Introduction Rivaroxaban is one of the most commonly used non-vitamin K antagonists for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …

Introduction Rivaroxaban is one of the most commonly used non-vitamin K antagonists for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …

Abstract Background and Objective Rivaroxaban is a novel oral anticoagulant widely used
for thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF). The present …

Rivaroxaban, a direct factor Xa inhibitor, is widely used for stroke prevention in patients with
non-valvular atrial fibrillation (NVAF). The aim of this study was to conduct a population …

Low-dose rivaroxaban has been used in Asian patients with direct oral anticoagulants
(DOACs) eligible for atrial fibrillation (AF). However, there are few pharmacokinetic (PK) data …

The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage
regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A …

Rivaroxaban is a direct‐acting oral anticoagulant approved to prevent strokes in patients
with atrial fibrillation. Dosage recommendations are approved for all adult patients to receive …

Rivaroxaban is one of the new oral anticoagulants (NOAC) for preventing stroke and
systemic embolism in patients with non-valvular atrial fibrillation. It has clear …

Objective: To establish the population pharmacokinetic (PPK) model of rivaroxaban in
patients with non-valvular atrial fibrillation, and provide a reference for clinical development …

To explore the anticoagulant effect and safety of utilizing different doses of rivaroxaban for
the treatment of patients with atrial fibrillation (AF) in the real world. A retrospective case …